RICHLAND, Wash., Sept. 25, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced a poster presentation at the 2017 Annual American Society for Radiation Oncology (ASTRO) Conference, the premier radiation oncology society in the world, being held on September 24-27, 2017. The poster, entitled "Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial", was presented by Dr. Brian Moran, Medical Director, Prostate Cancer Foundation of Chicago, Westmont, Illinois.

The trial's objective was to evaluate biochemical outcomes of a randomized group of low to intermediate risk, localized prostate cancer patients treated with permanent iodine-125 (I-125) or cesium-131 (Cs-131) brachytherapy. Median follow-up was 95 months for the 140-patient group. At nine years, the biochemical relapse-free survival (BRFS) was statistically equivalent for both groups, 89% for the I-125 group and 86% for the Cs-131 group (p=0.45). BRFS refers to a sensitive means of detecting persistent prostate cancer by measuring and trending prostate specific antigen (PSA) levels in the blood over time.

"The results of this trial, the longest data set available to date, demonstrates that permanent, low dose rate brachytherapy with Cesium-131 provides excellent PSA-based outcomes for low to intermediate risk localized prostate cancer patients. There was no significant difference in BRFS between these two isotopes over the nine-year follow-up period," said Dr. Moran.
Bill Cavanagh, Chief Scientific Officer of IsoRay commented, "This is the longest study conducted to-date for low risk prostate cancer patients treated with Cesium-131. The durable positive outcomes and statistically identical results support the consideration of Cesium-131 as a viable treatment choice for these patients. These results, combined with the results from the recently published University of Pittsburgh Medical Center study* that concluded that patients treated with Cesium-131 prostate brachytherapy are able to recover from prostate cancer treatment quickly and then maintain their baseline quality of life over the long term, suggest that brachytherapy with Cesium-131 should be considered by men with low risk prostate cancer."

Rad Oncology Homepage